RT Journal Article
SR Electronic
T1 Researching COVID to enhance recovery (RECOVER) pregnancy study: Rationale, objectives and design
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.24.23289025
DO 10.1101/2023.04.24.23289025
A1 Metz, Torri D.
A1 Clifton, Rebecca G.
A1 Gallagher, Richard
A1 Gross, Rachel S.
A1 Horwitz, Leora I.
A1 Jacoby, Vanessa L.
A1 Martin-Herz, Susanne P.
A1 Peralta-Carcelen, Myriam
A1 Reeder, Harrison T.
A1 Beamon, Carmen J.
A1 Bind, Marie-Abele
A1 Chan, James
A1 Chang, A. Ann
A1 Chibnik, Lori B.
A1 Costantine, Maged M.
A1 Fitzgerald, Megan L.
A1 Foulkes, Andrea S.
A1 Gibson, Kelly S.
A1 Güthe, Nick
A1 Habli, Mounira
A1 Hackney, David N.
A1 Hoffman, Matthew K.
A1 Hoffman, M. Camille
A1 Hughes, Brenna L.
A1 Katz, Stuart D.
A1 Laleau, Victoria
A1 Mallett, Gail
A1 Figueroa, Hector Mendez-
A1 Monzon, Vanessa
A1 Palatnik, Anna
A1 Palomares, Kristy T.S.
A1 Parry, Samuel
A1 Peralta-Carcelen, Myriam
A1 Pettker, Christian M.
A1 Plunkett, Beth A.
A1 Poppas, Athena
A1 Reddy, Uma M.
A1 Rouse, Dwight J.
A1 Saade, George R.
A1 Sandoval, Grecio J.
A1 Schlater, Shannon M.
A1 Sciurba, Frank C.
A1 Simhan, Hyagriv N.
A1 Skupski, Daniel W.
A1 Sowles, Amber
A1 Thaweethai, Tanayott
A1 Thomas, Gelise L.
A1 Thorp, John M.
A1 Tita, Alan T.
A1 Weiner, Steven J.
A1 Weigand, Samantha
A1 Yee, Lynn M.
A1 Flaherman, Valerie J.
A1 the RECOVER Initiative
YR 2023
UL http://medrxiv.org/content/early/2023/04/24/2023.04.24.23289025.abstract
AB Importance Pregnancy induces unique physiologic changes to the immune response and hormonal changes leading to plausible differences in the risk of developing post-acute sequelae of SARS-CoV-2 (PASC), or Long COVID. Exposure to SARS-CoV-2 during pregnancy may also have long-term ramifications for exposed offspring, and it is critical to evaluate the health outcomes of exposed children. The National Institutes of Health (NIH) Researching COVID to Enhance Recovery (RECOVER) Multi-site Observational Study of PASC aims to evaluate the long-term sequelae of SARS-CoV-2 infection in various populations. RECOVER- Pregnancy was designed specifically to address long-term outcomes in maternal-child dyads.Methods RECOVER-Pregnancy cohort is a combined prospective and retrospective cohort that proposes to enroll 2,300 individuals with a pregnancy during the COVID-19 pandemic and their offspring exposed and unexposed in utero, including single and multiple gestations. Enrollment will occur both in person at 27 sites through the Eunice Kennedy Shriver National Institutes of Health Maternal-Fetal Medicine Units Network and remotely through national recruitment by the study team at the University of California San Francisco (UCSF). Adults with and without SARS-CoV-2 infection during pregnancy are eligible for enrollment in the pregnancy cohort and will follow the protocol for RECOVER-Adult including validated screening tools, laboratory analyses and symptom questionnaires followed by more in-depth phenotyping of PASC on a subset of the overall cohort. Offspring exposed and unexposed in utero to SARS-CoV-2 maternal infection will undergo screening tests for neurodevelopment and other health outcomes at 12, 18, 24, 36 and 48 months of age. Blood specimens will be collected at 24 months of age for SARS-CoV-2 antibody testing, storage and anticipated later analyses proposed by RECOVER and other investigators.Discussion RECOVER-Pregnancy will address whether having SARS-CoV-2 during pregnancy modifies the risk factors, prevalence, and phenotype of PASC. The pregnancy cohort will also establish whether there are increased risks of adverse long-term outcomes among children exposed in utero.Registration NCT05172024Competing Interest StatementI have read the journal's policy and the authors of this manuscript have the following competing interests: Dr. Metz reports personal fees from Pfizer for her role as a medical consultant for a SARS-CoV-2 vaccination in pregnancy study, grants from Pfizer for role as a site PI for SARS-CoV-2 vaccination in pregnancy study, grants from Pfizer for role as a site PI for RSV vaccination in pregnancy study, and grants from Gestvision for role as a site PI for a preeclampsia study outside the submitted work. Dr. Horwitz reported serving as a member of the National Academy of Medicine Committee on the Long-Term Health Effects Stemming from COVID-19 and Implications for the Social Security Administration. Dr. Costantine reported receiving grant support for work not related to this paper from Baxter International and Siemens Healthcare and personal consulting fees not related to this paper from Progenity and Siemens Healthcare.Clinical TrialClinical Trial Registration: Unique identifier: NCT05172011 http://www.clinicaltrials.gov.Clinical Protocols https://recovercovid.org/sites/default/files/docs/PediatricProtocol.v2.3.pdf https://recovercovid.org/sites/default/files/docs/Adult.Protocol.v7.0.pdf Funding StatementNational Institutes of Health (NIH) Agreement OTA OT2HL161841 (ASF), OT2HL161847 (SDK), OT2HL156812 (N/A). https://www.nih.gov/ The funders did not and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Clinical Trial Registration: Unique identifier: NCT05172011 http://www.clinicaltrials.gov.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesNo datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion.